Reduction in hospital stay of chronic schizophrenic patients after long-term clozapine treatment

International Clinical Psychopharmacology

Volumn 20, Issue 3, 2005, Pages 157-161

  Ahn, Yong Min ^a,c   Chang, Jae Seung ^b   Kim, Yeni ^c   Lee, Kyu Young ^a,c   Kim, Jong Hoon ^d   Kim, Seong Chan ^a   Maeng, So Jin ^c   Kim, Yong Sik ^a,c  

^a Seoul National University College of Medicine   (South Korea)

^b Yong in Mental Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Gachon University   (South Korea)

Author keywords

Clozapine; Outcome; Rehospitalization; Schizophrenia

Indexed keywords

CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; CHRONIC DISEASE; FEMALE; HOSPITALIZATION; HUMAN; KOREA; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT CARE; PRIORITY JOURNAL; RELAPSE; RELIABILITY; SCHIZOPHRENIA; SOCIAL INTERACTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; CLOZAPINE; FEMALE; HUMANS; LENGTH OF STAY; LONG-TERM CARE; MALE; MIDDLE AGED; PATIENT READMISSION; PSYCHIATRIC STATUS RATING SCALES; RECURRENCE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 17644366792     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200505000-00006     Document Type: Article

References (27)

1. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P (1993). Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 15:917-926.
2. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
3. Beasley CM Jr, Tollefson GD, Tran PV (1997). Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 58 (suppl 10):7-12.
4. Bellack AS, Schooler NR, Marder SR, Kane JM, Brown CH, Yang Y (2004). Do clozapine and risperidone affect social competence and problem solving? Am J Psychiatry 161:364-367.
5. Carpenter MD, Mulligan JC, Bader IA, Meinzer AE (1985). Multiple admissions to an urban psychiatric center: a comparative study. Hosp Commun Psychiatry 36:1305-1308.
6. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA (1995). Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 152:827-832.
7. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M, et al. (2003). Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J Clin Psychiatry 64:451-458.
8. Conley RR, Love RC, Kelly DL, Bartko JJ (1999). Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 156:863-868.
9. Conley RR, Kelly DL, Love RC, McMahon RP (2003). Rehospitalization risk with second-generation and depot antipsychotics. Ann Clin Psychiatry 15:23-31.
10. Essock SM, Hargreaves WA, Covell NH, Goethe J (1996). Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharmacol Bull 32:683-697.
11. Gaszner P, Makkos Z (2004). Clozapine maintenance therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:465-469.
12. Hogarty GE (1993). Prevention of relapse in chronic schizophrenic patients. J Clin Psychiatry 54 (suppl):18-23.
13. Keck PE Jr, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, et al. (1995). Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 56:466-470.
14. Lorei TW, Gurel L (1973). Demographic characteristics as predictors of posthospital employment and readmission. J Consult Clin Psychol 40: 426-430.
15. Meltzer HY, Burnett S, Bastani B, Ramirez LF (1990). Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Commun Psychiatry 41:892-897.
16. Meltzer HY, Lee MA, Ranjan R (1994). Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr Scand Suppl 384:95-101.
17. Meltzer HY, Alphs L, Altamura AC (2003). International suicide prevention trial (InterSePT): reduced suicidality in schizophrenia with clozapine treatment. Arch Gen Psychiatry 59:82-91.
18. Mosher LR, Menn AZ (1978). Community residential treatment for schizophrenia: two-year follow-up. Hosp Comm Psychiatry 29:715-723.
19. Mosher LR, Menn A, Matthew SM (1975). Soteria: evaluation of a home-based treatment for schizophrenia. Am J Orthopsychiatry 45:455-467.
20. Olfson M, Mechanic D, Boyer CA, Hansell S, Walkup J, Weiden PJ (1999). Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis 187:721-729.
21. Pollack S, Woerner MG, Howard A, Fireworker RB, Kane JM (1998). Clozapine reduces rehospitalization among schizophrenia patients. Psychopharmacol Bull 34:89-92.
22. Postrado LT, Lehman AF (1995). Quality of life and clinical predictors of rehospitalization of persons with severe mental illness. Psychiatr Serv 46:1161-1165.
23. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M (2001). Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 158:266-269.
24. Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, et al. (1997). Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Arch Gen Psychiatry 54:453-463.
25. Suzuki Y, Yasumura S, Fukao A, Otani K (2003). Associated factors of rehospitalization among schizophrenic patients. Psychiatry Clin Neurosci 57:555-561.
26. Wahlbeck K, Cheine M, Essali MA (2000). Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev CD000059.
27. Weiden PJ, Olfson M (1995). Cost of relapse in schizophrenia. Schizophr Bull 21:419-429.